Skip to main content
OpenTrials

Clinical trial condition

Malignant Melanoma

Explore clinical trials studying Malignant Melanoma. Study availability and eligibility vary by location and protocol.

168 public trials 20 recruiting studies
Refine in advanced search Browse all conditions

Malignant Melanoma trial results

Completed

4SC-202 in Combination With Pembrolizumab in Patients Primary Refractory/Non-responding to Prior Anti-PD-1 Therapy

NCT03278665

Conditions
Malignant Melanoma, Melanoma, Neoplasms, +10 more
Locations
  • Universitätsklinikum Essen Essen, Germany
  • Medizinische Hochschule Hannover Hanover, Germany
  • Universitätsklinikum Heidelberg Heidelberg, Germany
  • Klinikum der Universität München München, Germany
View Trial Details
Completed

Cobimetinib (Targeted Therapy) Plus Atezolizumab (Immunotherapy) in Participants With Advanced Melanoma Whose Cancer Has Worsened During or After Treatment With Previous Immunotherapy and Atezolizumab Monotherapy in Participants With Previously Untreated Advanced Melanoma

NCT03178851

Conditions
Malignant Melanoma, Melanoma, Neoplasms, +10 more
Locations
  • HonorHealth Research Institute - Bisgrove Scottsdale, Arizona, United States
  • University of Colorado Hospital - Anschutz Cancer Pavilion Aurora, Colorado, United States
  • Karmanos Cancer Institute Detroit, Michigan, United States
  • Washington University School of Medicine St Louis, Missouri, United States
View all 43 locations
View Trial Details
Completed

PLX3397 KIT in Acral aNd mucOsal Melanoma

NCT02071940

Conditions
Malignant Melanoma, Melanoma, Neoplasms, +10 more
Locations
  • The Christie NHS Foundation Trust Manchester, Greater Manchester, United Kingdom
  • The Beatson West of Scotland Cancer Centre Glasgow, Scotland, United Kingdom
  • Abertawe Bro Morgannwg University Health Board, Singleton Hospital Swansea, Wales, United Kingdom
  • St James' University Hospital Leeds, Yorkshire, United Kingdom
View Trial Details
Completed

Dose-escalation Study of Combination BMS-936558 (MDX-1106) and Ipilimumab in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma

NCT01024231

Conditions
Malignant Melanoma, Melanoma, Neoplasms, +10 more
Locations
  • Yale University School Of Medicine New Haven, Connecticut, United States
  • Medstar Georgetown-Lombardi Comprehensive Cancer Center Washington D.C., District of Columbia, United States
  • Memorial Sloan Kettering Nassau New York, United States
  • Hillman Cancer Research Pavilion Pittsburgh, Pennsylvania, United States
View Trial Details
Completed

A Personal Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer

NCT02897765

Conditions
Bladder Tumors, Bronchial Neoplasms, Carcinoma, Bronchogenic, +32 more
Locations
  • City of Hope Duarte, California, United States
  • UCLA Medical Center Los Angeles, California, United States
  • University of California San Francisco San Francisco, California, United States
  • Massachusetts General Hospital Boston, Massachusetts, United States
View Trial Details
Completed

Encorafenib + Binimetinib + Pembrolizumab in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma

NCT02902042

Conditions
Malignant Melanoma, Melanoma, Neoplasms, +10 more
Locations
  • Universitätsklinikum Freiburg Freiburg im Breisgau, Baden-Wurttemberg, Germany
  • Klinikum Augsburg Süd Augsburg, Bavaria, Germany
  • Klinikum rechts der Isar München, Bavaria, Germany
  • Klinikum Nürnberg Nord Nuremberg, Bavaria, Germany
View Trial Details

Related conditions